Associations Between TNFSF13B Polymorphisms and Primary Sjögren's Syndrome Susceptibility in Primary Sjögren's Syndrome Patients: A Meta-analysis

Overview

Journal Immun Inflamm Dis

Specialties Allergy & Immunology
Infectious Diseases

Date 2023 Dec 29

PMID 38156381

Authors

Anhao Zheng

Naiwen Hu

Jing Xu

Ye Yuan

Shumin Zhang

Wenbin Chen

Yanyan Bai

Hongsheng Sun

Affiliations

Soon will be listed here.

Abstract

Objective: B-cell activating factor (BAFF) is a key regulator of primary Sjögren's syndrome (pSS), which is characterized by B-lymphocyte hyperactivity. BAFF, also known as tumor necrosis factor ligand superfamily member 13B, is encoded by TNFSF13B. This study aimed to explore the possible relationships between five single-nucleotide polymorphisms (SNPs) of TNFSF13B (rs9514827, rs1041569, rs9514828, rs1224141, and rs12583006) and pSS susceptibility.

Methods: We searched the following databases for articles on TNFSF13B polymorphism and pSS published up to January 2023: PubMed, Cochrane, Elsevier, Web of Science, CNKI, CQVIP, and WanFang. The odds ratios (with 95% confidence intervals) of genotypes and SNP alleles of TNFSF13B were investigated in patients with pSS to determine their relationships with pSS.

Results: This meta-analysis employing the fixed-effect model comprised three studies of pSS patients and randomly selected healthy controls (HCs), revealing statistically significant relationships between pSS susceptibility and two SNPs: rs1041569 and rs12583006. Because rs1041569 was not in Hardy-Weinberg equilibrium in the HC group, it was eliminated from the analysis.

Conclusions: Polymorphisms in the BAFF (TNFSF13B) gene were related to vulnerability to pSS among pSS patients and HCs alike. The SNP rs12583006 was significantly related to pSS susceptibility in pSS patients.

Citing Articles

Vitamin D in Primary Sjogren's Syndrome (pSS) and the Identification of Novel Single-Nucleotide Polymorphisms Involved in the Development of pSS-Associated Diseases.

Dabravolski S, Churov A, Starodubtseva I, Beloyartsev D, Kovyanova T, Sukhorukov V Diagnostics (Basel). 2024; 14(18).

PMID: 39335717 PMC: 11431467. DOI: 10.3390/diagnostics14182035.

A comprehensive review of Sjögren's syndrome: Classification criteria, risk factors, and signaling pathways.

Zhao T, Zhang R, Li Z, Qin D, Wang X Heliyon. 2024; 10(17):e36220.

PMID: 39286095 PMC: 11403439. DOI: 10.1016/j.heliyon.2024.e36220.

Associations between TNFSF13B polymorphisms and primary Sjögren's syndrome susceptibility in primary Sjögren's syndrome patients: A meta-analysis.

Zheng A, Hu N, Xu J, Yuan Y, Zhang S, Chen W Immun Inflamm Dis. 2023; 11(12):e1103.

PMID: 38156381 PMC: 10698818. DOI: 10.1002/iid3.1103.

References

Carrillo-Ballesteros F, Palafox-Sanchez C, Franco-Topete R, Munoz-Valle J, Orozco-Barocio G, Martinez-Bonilla G . Expression of BAFF and BAFF receptors in primary Sjögren's syndrome patients with ectopic germinal center-like structures. Clin Exp Med. 2020; 20(4):615-626. DOI: 10.1007/s10238-020-00637-0. View

Baldini C, Ferro F, Elefante E, Bombardieri S . Biomarkers for Sjögren's syndrome. Biomark Med. 2018; 12(3):275-286. DOI: 10.2217/bmm-2017-0297. View

Mavragani C . Mechanisms and New Strategies for Primary Sjögren's Syndrome. Annu Rev Med. 2017; 68:331-343. DOI: 10.1146/annurev-med-043015-123313. View

Daridon C, Devauchelle V, Hutin P, Le Berre R, Martins-Carvalho C, Bendaoud B . Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum. 2007; 56(4):1134-44. DOI: 10.1002/art.22458. View

Kintrilis N, Gravani F, Rapti A, Papaioannou M, Flessa C, Nezos A . Subclinical atherosclerosis profiles in rheumatoid arthritis and primary Sjögren's syndrome: the impact of BAFF genetic variations. Rheumatology (Oxford). 2022; 62(2):958-968. DOI: 10.1093/rheumatology/keac337. View

Mackay F, Sierro F, Grey S, Gordon T . The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun. 2004; 8:243-65. DOI: 10.1159/000082106. View

Steri M, Orru V, Idda M, Pitzalis M, Pala M, Zara I . Overexpression of the Cytokine BAFF and Autoimmunity Risk. N Engl J Med. 2017; 376(17):1615-1626. PMC: 5605835. DOI: 10.1056/NEJMoa1610528. View

Zheng A, Hu N, Xu J, Yuan Y, Zhang S, Chen W . Associations between TNFSF13B polymorphisms and primary Sjögren's syndrome susceptibility in primary Sjögren's syndrome patients: A meta-analysis. Immun Inflamm Dis. 2023; 11(12):e1103. PMC: 10698818. DOI: 10.1002/iid3.1103. View

Teos L, Alevizos I . Genetics of Sjögren's syndrome. Clin Immunol. 2017; 182:41-47. PMC: 5660941. DOI: 10.1016/j.clim.2017.04.018. View

10.

Gottenberg J, Busson M, Cohen-Solal J, Lavie F, Abbed K, Kimberly R . Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome. Ann Rheum Dis. 2005; 64(7):1050-5. PMC: 1755548. DOI: 10.1136/ard.2004.030643. View

11.

James J, Guthridge J, Chen H, Lu R, Bourn R, Bean K . Unique Sjögren's syndrome patient subsets defined by molecular features. Rheumatology (Oxford). 2019; 59(4):860-868. PMC: 7188221. DOI: 10.1093/rheumatology/kez335. View

12.

Nezos A, Papageorgiou A, Fragoulis G, Ioakeimidis D, Koutsilieris M, Tzioufas A . B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. J Autoimmun. 2013; 51:89-98. DOI: 10.1016/j.jaut.2013.04.005. View

13.

Vincent F, Saulep-Easton D, Figgett W, Fairfax K, Mackay F . The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013; 24(3):203-15. PMC: 7108297. DOI: 10.1016/j.cytogfr.2013.04.003. View

14.

Nikolov N, Illei G . Pathogenesis of Sjögren's syndrome. Curr Opin Rheumatol. 2009; 21(5):465-70. PMC: 2766246. DOI: 10.1097/BOR.0b013e32832eba21. View

15.

Jonsson M, Szodoray P, Jellestad S, Jonsson R, Skarstein K . Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome. J Clin Immunol. 2005; 25(3):189-201. DOI: 10.1007/s10875-005-4091-5. View

16.

Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T . The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis. 2003; 62(2):168-71. PMC: 1754442. DOI: 10.1136/ard.62.2.168. View

17.

Gottenberg J, Sellam J, Ittah M, Lavie F, Proust A, Zouali H . No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjögren's syndrome. Arthritis Res Ther. 2006; 8(1):R30. PMC: 1526574. DOI: 10.1186/ar1884. View

18.

Szodoray P, Jonsson R . The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjögren's syndrome. Scand J Immunol. 2005; 62(5):421-8. DOI: 10.1111/j.1365-3083.2005.01688.x. View

19.

Ota M, Duong B, Torkamani A, Doyle C, Gavin A, Ota T . Regulation of the B cell receptor repertoire and self-reactivity by BAFF. J Immunol. 2010; 185(7):4128-36. PMC: 3263398. DOI: 10.4049/jimmunol.1002176. View

20.

Mariette X, Gottenberg J . Pathogenesis of Sjögren's syndrome and therapeutic consequences. Curr Opin Rheumatol. 2010; 22(5):471-7. DOI: 10.1097/BOR.0b013e32833c36c5. View